VJHemOnc Podcast

Updates on the diagnosis, risk stratification and treatment of lower-risk MDS

Oct 6, 2023

Sanam Loghavi, medical doctor from The University of Texas MD Anderson Cancer Center, discusses updates on the diagnosis, risk stratification, and treatment of lower-risk MDS. Topics include the challenges in managing LR-MDS, the importance of accurate diagnosis and risk stratification using the IPSS-M model, FDA approval of Luspattersept frontline therapy, constructing pathology reports for optimal patient care, and incorporating various diagnostic tools for diagnosing LR-MDS.

19:05

Creator website

Episode guests

Sanam Loghavi

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

Thorough diagnosis and risk stratification are crucial for managing lower-risk MDS, including comprehensive clinical history and genetic analysis.

Low-risk MDS patients have better overall survival, but still have a risk of transforming to AML, emphasizing the need for accurate risk assessment.

Deep dives

Diagnosis and Risk Stratification of MDS

The podcast discusses the importance of a thorough diagnosis and risk stratification for lower-risk myelodysplastic syndromes (MDS). The speakers emphasize the need for a comprehensive clinical history, as well as key diagnostic tests such as peripheral blood smear, bone marrow biopsy, and flow cytometry. They also highlight the significance of genetic analysis, including cytogenetic abnormalities and somatic mutations. The evolving field of molecular iteration, specifically the IPSSM system, is mentioned as a powerful tool in risk stratifying patients with MDS.

Introduction

3min

Testing Methods and Risk Stratification in Lower-Risk MDS

6min

FDA Approval of Luspattersept for Frontline Therapy in Lower-Risk MDS

6min

Constructing Pathology Reports for Optimal Patient Care

2min

Incorporating all available information and pathology tricks for diagnosing lower-risk MDS

3min

The treatment and management of lower-risk myelodysplastic syndromes (LR-MDS) has remained a challenge in the field, and several studies are being conducted with the goal of improving the understanding of this disease. Furthermore, there have been recent updates to classification systems for MDS, including the Molecular International Prognostic Scoring System (IPSS-M).

In this podcast, you will hear from Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Rami Komrokji, MD, Moffitt Cancer Center, Tampa, FL, who discuss recent updates in the diagnosis, risk stratification and treatment of LR-MDS. This discussion was filmed at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

The post Updates on the diagnosis, risk stratification and treatment of lower-risk MDS appeared first on VJHemOnc.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.

VJHemOnc Podcast

Updates on the diagnosis, risk stratification and treatment of lower-risk MDS

Episode guests

Podcast summary created with Snipd AI

Quick takeaways

Deep dives

Diagnosis and Risk Stratification of MDS

Low Risk vs. High Risk MDS

Treatment Approaches for Low Risk MDS

Remember Everything You Learn from Podcasts